Publicação
New Trends in Inflammatory Bowel Disease
| Resumo: | Inflammatory bowel disease (IBD) is a chronic idiopathic inflammatory disease of the gastrointestinal (GI) tract. In the past decade a shift in the treatment paradigm of IBD has ensued. The availability of drugs capable of inducing mucosal healing, combined with the recognition that IBD is not an intermittent disease, but rather a progressive one causing bowel damage and disability, led us to a more stringent strategy. Tailored therapy with more aggressive treatment in high-risk patients, treating beyond symptoms, intervening early before damage occurs, optimizing therapeutic regimens, and actively pursuing sustained remission and sustained control of inflammation are strategies that are slowly being incorporated in our clinical practice. Furthermore, new drugs targeting different immunological pathways, such a s vedolizumab, have recently been approved and therefore more therapeutic resources for patients failing anti-tumour necrosis factor alpha (anti-TNFa) agents will be available. The future years look promising for IBD. Hopefully the new trends in IBD management, combined with new drugs, will make possible to change the course of disease and provide better therapy and quality of life for patients suffering from this disabling disease. |
|---|---|
| Autores principais: | Palmela,Carolina |
| Outros Autores: | Torres,Joana; Cravo,Marilia |
| Assunto: | Antibodies Monoclonal Colitis Ulcerative Crohn Disease Inflammatory Bowel Diseases Molecular Targeted Therapy Drug Monitoring |
| Ano: | 2015 |
| País: | Portugal |
| Tipo de documento: | artigo |
| Tipo de acesso: | acesso aberto |
| Instituição associada: | Fundação para a Ciência e Tecnologia |
| Idioma: | inglês |
| Origem: | SciELO Portugal |
| _version_ | 1868441987492872192 |
|---|---|
| author | Palmela,Carolina |
| author2 | Torres,Joana Cravo,Marilia |
| author2_role | author author |
| author_facet | Palmela,Carolina Torres,Joana Cravo,Marilia |
| author_role | author |
| country_str | PT |
| creators_json_txt | [{\"Person.name\":\"Palmela,Carolina\"},{\"Person.name\":\"Torres,Joana\"},{\"Person.name\":\"Cravo,Marilia\"}] |
| datacite.creators.creator.creatorName.fl_str_mv | Palmela,Carolina Torres,Joana Cravo,Marilia |
| datacite.rights.fl_str_mv | http://purl.org/coar/access_right/c_abf2 |
| datacite.subjects.subject.fl_str_mv | Antibodies Monoclonal Colitis Ulcerative Crohn Disease Inflammatory Bowel Diseases Molecular Targeted Therapy Drug Monitoring |
| datacite.titles.title.fl_str_mv | New Trends in Inflammatory Bowel Disease |
| dc.creator.none.fl_str_mv | Palmela,Carolina Torres,Joana Cravo,Marilia |
| dc.format.none.fl_str_mv | text/html |
| dc.identifier.none.fl_str_mv | http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452015000300005 |
| dc.language.none.fl_str_mv | eng |
| dc.publisher.none.fl_str_mv | Sociedade Portuguesa de Gastrenterologia |
| dc.rights.none.fl_str_mv | http://purl.org/coar/access_right/c_abf2 |
| dc.source.none.fl_str_mv | GE-Portuguese Journal of Gastroenterology v.22 n.3 2015 |
| dc.subject.none.fl_str_mv | Antibodies Monoclonal Colitis Ulcerative Crohn Disease Inflammatory Bowel Diseases Molecular Targeted Therapy Drug Monitoring |
| dc.title.fl_str_mv | New Trends in Inflammatory Bowel Disease |
| dc.type.none.fl_str_mv | http://purl.org/coar/resource_type/c_6501 |
| description | Inflammatory bowel disease (IBD) is a chronic idiopathic inflammatory disease of the gastrointestinal (GI) tract. In the past decade a shift in the treatment paradigm of IBD has ensued. The availability of drugs capable of inducing mucosal healing, combined with the recognition that IBD is not an intermittent disease, but rather a progressive one causing bowel damage and disability, led us to a more stringent strategy. Tailored therapy with more aggressive treatment in high-risk patients, treating beyond symptoms, intervening early before damage occurs, optimizing therapeutic regimens, and actively pursuing sustained remission and sustained control of inflammation are strategies that are slowly being incorporated in our clinical practice. Furthermore, new drugs targeting different immunological pathways, such a s vedolizumab, have recently been approved and therefore more therapeutic resources for patients failing anti-tumour necrosis factor alpha (anti-TNFa) agents will be available. The future years look promising for IBD. Hopefully the new trends in IBD management, combined with new drugs, will make possible to change the course of disease and provide better therapy and quality of life for patients suffering from this disabling disease. |
| dirty | 0 |
| eu_rights_str_mv | openAccess |
| format | article |
| id | scielopt_8a6967bf8bf3ff1ccff62f5c90408bcf |
| identifier.url.fl_str_mv | http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452015000300005 |
| instacron_str | SciELO |
| institution | Fundação para a Ciência e Tecnologia |
| instname_str | Fundação para a Ciência e Tecnologia |
| language | eng |
| network_acronym_str | scielopt |
| network_name_str | SciELO Portugal |
| oai_identifier_str | oai:scielo:S2341-45452015000300005 |
| organization_str_mv | urn:organizationAcronym:scielo |
| person_str_mv | Palmela,Carolina Torres,Joana Cravo,Marilia |
| publishDate | 2015 |
| publisher.none.fl_str_mv | Sociedade Portuguesa de Gastrenterologia |
| reponame_str | SciELO Portugal |
| repository_id_str | urn:repositoryAcronym:scielopt |
| service_str_mv | urn:repositoryAcronym:scielopt |
| spelling | New Trends in Inflammatory Bowel DiseasePalmela,CarolinaTorres,JoanaCravo,MariliaAntibodiesMonoclonalColitisUlcerativeCrohn DiseaseInflammatory Bowel DiseasesMolecular Targeted TherapyDrug Monitoringopen accesshttp://purl.org/coar/access_right/c_abf2http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452015000300005URLhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452015000300005URLHasVersion2015-06-01Inflammatory bowel disease (IBD) is a chronic idiopathic inflammatory disease of the gastrointestinal (GI) tract. In the past decade a shift in the treatment paradigm of IBD has ensued. The availability of drugs capable of inducing mucosal healing, combined with the recognition that IBD is not an intermittent disease, but rather a progressive one causing bowel damage and disability, led us to a more stringent strategy. Tailored therapy with more aggressive treatment in high-risk patients, treating beyond symptoms, intervening early before damage occurs, optimizing therapeutic regimens, and actively pursuing sustained remission and sustained control of inflammation are strategies that are slowly being incorporated in our clinical practice. Furthermore, new drugs targeting different immunological pathways, such a s vedolizumab, have recently been approved and therefore more therapeutic resources for patients failing anti-tumour necrosis factor alpha (anti-TNFa) agents will be available. The future years look promising for IBD. Hopefully the new trends in IBD management, combined with new drugs, will make possible to change the course of disease and provide better therapy and quality of life for patients suffering from this disabling disease.Sociedade Portuguesa de GastrenterologiaGE-Portuguese Journal of Gastroenterology v.22 n.3 2015text/htmlengjournal articlehttp://purl.org/coar/resource_type/c_6501literature |
| spellingShingle | New Trends in Inflammatory Bowel Disease Palmela,Carolina Antibodies Monoclonal Colitis Ulcerative Crohn Disease Inflammatory Bowel Diseases Molecular Targeted Therapy Drug Monitoring |
| status | SINGLETON |
| subject.fl_str_mv | Antibodies Monoclonal Colitis Ulcerative Crohn Disease Inflammatory Bowel Diseases Molecular Targeted Therapy Drug Monitoring |
| title | New Trends in Inflammatory Bowel Disease |
| title_full | New Trends in Inflammatory Bowel Disease |
| title_fullStr | New Trends in Inflammatory Bowel Disease |
| title_full_unstemmed | New Trends in Inflammatory Bowel Disease |
| title_short | New Trends in Inflammatory Bowel Disease |
| title_sort | New Trends in Inflammatory Bowel Disease |
| topic | Antibodies Monoclonal Colitis Ulcerative Crohn Disease Inflammatory Bowel Diseases Molecular Targeted Therapy Drug Monitoring |
| topic_facet | Antibodies Monoclonal Colitis Ulcerative Crohn Disease Inflammatory Bowel Diseases Molecular Targeted Therapy Drug Monitoring |
| url | http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452015000300005 |
| visible | 1 |